Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 470

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 470
---
 15 years of experience in business development, entrepreneurship, corporate strategy, and strategic innovation across Latin America. Since 2022, Mr. Calmet has served as CEO of Heritas Argentina, where he significantly transformed the company into a leader in precision medicine. He co -developedRewell, a health prevention service, and successfully restructured the business to support growth and lay a robust foundation for OmnigenicsAI. Before his tenure at Heritas Argentina, Mr. Calmet spearheaded business development and product strategy efforts to scale a fintech SaaS product in Latin America. Additionally, he played a critical role in driving innovation and managing organizational change at an innovation hub within a South American conglomerate, valued at US$12.7 billion. Mr. Calmet’s early career included strategic roles in a search fund, acquiring and developing a US$25 million project in Chile, and developing and launching financial products within a financial institution. Mr. Calmet received a Master of Business Administration from the Kellogg School of Management and a Bachelor’s of Science in Industrial Management from Purdue University. Kyle Bransfield.Upon the closing of the Business Combination, Mr.Bransfield will assume the role of Chief Financial Officer and director of the Company. Please see “ Business of APx and Certain Information about APx — Directors and Executive Officers.” Martin Vazquez.Upon the Closing of the Business Combination, Mr. Vazquez will assume the role of Chief Science Officer of the Company. Mr. Vazquez co -foundedHeritas Argentina in 2015 and has been serving as its Chief Science Officer since then, bringing a wealth of experience in biotechnology and leadership to the company. Prior to this, he held the same position at Bioceres from 2011 to 2015. Mr. Vazquez earned his Ph.D. in Molecular Biology and

245 Genomics from the University of Buenos Aires in 1996, and since then has deepened his expertise in next -generationsequencing, bioinformatics, and biotechnology. His career highlights include directing significant research and development projects within the biotech sector, particularly with Conicet since 1999, where he led high -impactconsortia in Argentina and played a pivotal role in fostering innovation as an industry advisor. With certifications in strategic management and entrepreneurship obtained in 2020, Vazquez combines his scientific expertise with business acumen. His academic contributions are substantial, including supervising over ten Ph.D. students and teaching at the University of Buenos Aires